FDA accepts Ocular application for expanded use of Dextenza

• The FDA accepts for review Ocular Therapeutix's (NASDAQ:OCUL) supplemental marketing application seeking approval to use DEXTENZA (dexamethasone ophthalmic insert) to treat ocular inflammation following ophthalmic surgery. The agency's action date is November 10.
• The FDA approved DEXTENZA in December 2018 for ocular pain following ophthalmic surgery.
• Shares are up 2% premarket on light volume.